ESMO

Home Tag

Copia de Copia de Copia de Banner web VHIO (12)

Preliminary results from a first-in-human phase 1/2 trial show promise of novel BiDAC ™ degrader designed to overcome treatment resistance in solid tumors

Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…

Dra. Elena Garralda con bata VHIO, fondo difuminado

Elena Garralda’s latest ESMO On target column: the promise of immuno-oncology in the neoadjuvant setting

Published by ESMO’s Daily Reporter, Elena Garralda’s latest On target column explores the promise of neoadjuvant immunotherapy in the treatment…